Markets

Repros' Q3 Loss Narrower than Expected, Pipeline in Focus

Market Data on both Smart Phone and Paper

Repros Therapeutics Inc.RPRX reported a loss of 27 cents per share in the third quarter of 2015, narrower than the year-ago loss of 32 cents and the Zacks Consensus Estimate of a loss of 29 cents.

Repros Therapeutics Inc. (RPRX) - Earnings Surprise | FindTheCompany

Third-quarter revenues (which consisted entirely of interest income) decreased 50% from the year-ago quarter to $1,000.

Quarterly Details

During the reported quarter, research & development expenses decreased 12.3% year over year to $5.5 million primarily due to the completion of all phase III studies on enclomiphene, which was partially offset by increased expenses related to the development of Proellex.

General and administrative expenses also decreased almost 14% year over year to $1.1 million, mainly due to decreased professional services costs.

Enclomiphene is Repros' lead pipeline candidate that is under FDA review for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.

However, late last month, Repros received a huge setback when the FDA cancelled an advisory panel meeting with the Division of Bone, Reproductive and Urologic Products that was scheduled for Nov 3 for enclomiphene. The FDA informed that certain concerns cropped up late in the review related to the bio-analytical method validation that could affect interpretability of certain pivotal study data. A final response from the FDA is expected by Nov 30.

Meanwhile, Repros' second pipeline candidate, Proellex, is being developed for the treatment of uterine fibroids and endometriosis. Proellex is currently in a couple of phase IIb efficacy studies (both oral and vaginal administration) for the treatment of uterine fibroids. The company expects to complete the first course of treatment in both studies by the second quarter of 2016. Additionally, the company expects a phase II study on Proellex (low-dose oral administration) for endometriosis to be fully enrolled by the first quarter of 2016.

With no approved product in the company's portfolio at the moment and enclomiphene being its lead pipeline candidate, investor focus will remain on further regulatory updates regarding enclomiphene.

Repros is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF , Achillion Pharmaceuticals, Inc. ACHN and Anika Therapeutics Inc. ANIK . All three hold a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACTELION LTD (ALIOF): Free Stock Analysis Report

REPROS THERAPEU (RPRX): Free Stock Analysis Report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ANIK ACHN

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More